CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have T-cell lymphoma that is CD7-positive and has not responded to or come back after standard chemotherapy.
- You are between 14 and 70 years old.
- You are well enough to be up and about at least half the day (ECOG score 0-2).
- Your life expectancy is at least 2 months (60 days).
- You can understand and sign the consent form, or if under 18, your legal guardian can sign.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
This trial tests a new CAR T-cell treatment for T-cell lymphoma that has come back or hasn't responded to standard treatments. The treatment is designed to target cancer cells that have a protein called CD5 on their surface.
This trial tests a new immune cell therapy (CAR T-cells) that targets CD5 found on certain T-cell cancers. It may be an option for people whose cancer has not responded to other treatments.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are reprogrammed to find and destroy T-cell leukemia or lymphoma cells that have the CD5 protein. It may be an option if your cancer has come back or hasn't responded to other treatments.
Hear when a new T-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.